Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Current Assets (2016 - 2025)

Zevra Therapeutics' Current Assets history spans 11 years, with the latest figure at $223.0 million for Q4 2025.

  • For Q4 2025, Current Assets rose 159.23% year-over-year to $223.0 million; the TTM value through Dec 2025 reached $223.0 million, up 159.23%, while the annual FY2025 figure was $223.0 million, 159.23% up from the prior year.
  • Current Assets reached $223.0 million in Q4 2025 per ZVRA's latest filing, down from $225.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $226.3 million in Q2 2025 to a low of -$426000.0 in Q3 2022.
  • Average Current Assets over 5 years is $111.9 million, with a median of $96.1 million recorded in 2022.
  • Peak YoY movement for Current Assets: soared 1553.12% in 2021, then plummeted 100.32% in 2022.
  • A 5-year view of Current Assets shows it stood at $115.1 million in 2021, then fell by 19.31% to $92.8 million in 2022, then decreased by 6.35% to $86.9 million in 2023, then dropped by 1.05% to $86.0 million in 2024, then soared by 159.23% to $223.0 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Current Assets are $223.0 million (Q4 2025), $225.1 million (Q3 2025), and $226.3 million (Q2 2025).